Literature DB >> 8235067

Effect of diacylglycerol kinase inhibitor, R59022 on cytosolic free calcium level and force development in guinea pig taenia coli.

K Nobe1, H Ohata, K Momose.   

Abstract

We previously described that carbachol (CCh) increased intracellular phosphatidic acid (PA) in guinea pig taenia coli and the increase was inhibited by diacylglycerol (DG) kinase inhibitor, R59022. The present study was conducted to clarify the role of DG kinase in CCh-induced increase in cytosolic free calcium and force development. Application of CCh to taenia coli induced transient increase in calcium level and contraction followed by sustained and lower calcium level and smaller contraction, and R59022 inhibited the latter responses specifically. The sustained responses were also evoked by 50 mM KCl, but these responses were slightly inhibited by R59022. Inhibition of calcium influx reduced responses to CCh but not KCl. Therefore, we consider that the sustained contraction induced by CCh is attributed to activation of DG kinase which generates PA and accelerates calcium influx.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8235067

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  3 in total

1.  Novel diacylglycerol kinase inhibitor selectively suppressed an U46619-induced enhancement of mouse portal vein contraction under high glucose conditions.

Authors:  Koji Nobe; Mari Miyatake; Hiromi Nobe; Yasushi Sakai; Junko Takashima; Kazutaka Momose
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

2.  Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer.

Authors:  Benjamin Purow
Journal:  Clin Cancer Res       Date:  2015-09-29       Impact factor: 12.531

3.  Hyper-reactivity of diacylglycerol kinase is involved in the dysfunction of aortic smooth muscle contractility in streptozotocin-induced diabetic rats.

Authors:  Koji Nobe; Yasushi Sakai; Yoshiaki Maruyama; Kazutaka Momose
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.